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ANATOMY OF PLACENTATION 
(A) Lobular architecture 
From end of first trimester the placenta attains its 
definitive architecture but continues to grow thereafter 
(Pangiel 1986). 
It becomes divided into 15 - 30 lobules by septa divided by 
a combination of trophoblast and decidual elements. 
To each lobular space there are 1 - 3 cotyledons which are 
the fetal placental units of the branched villous tree. 
(B) Vascular Anatomy 
The maternal and fetal blood streams are separated by a 
placental barrier. The fetal blood is contained in the 
placental villi and the maternal blood circulates in the 
intervillous space. 
When the blastocyst implants, the endometrium is in the 
luteal phase and the spiral arteries lie immediately below 
the superficial capillary plexus. 
Several days elapse before the invading trophoblast effects 
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free communication between the maternal arterial system and 
the developing intervillous space of the placenta. During 
this time the arteries become more coiled as a preparation 
for stretching out in the last trimester as the uterus 
expands. During this early period the arteries undergo a 
marked dilation. This progressive dilation (Brosens 1967) 
is achieved in two phases. In the first trimester there is 
a transmural colonisation of the distal spiral walls by 
trophoblast and the migration of trophoblast 
(cytotrophoblast) in the lumen of the arteries. The cells 
migrate down the inner walls of the arteries (a process 
likened to wax dripping down a candle) to almost the 
myometrial segments. Initially the vascular endothelium is 
involved then the media of the arteries becomes invaded by 
cytotrophoblast and finally the bulk of the musculo elastic 
tissue in the wall of the artery is replaced by fibrinoid 
tissue. 
4 
At 14 - 16 weeks there is a similar process of migration 
into the myometrial portion of the spiral arteries (second 
wave of trophoblastic migration) as far as their origin from 
the parent radial arteries. 
This adaptive process has thus changed spiral arteries to 
utero-placental arteries and a low pressure, high 
conductance vascular system has been formed. (See Figure 1) 
CHAPTER 2 
PHYSIOLOGY OF UTEROPLACENTAL FLOW 
REGULATION OF UTEROPLACENTAL FLOW 
1. Maternal 
The regulation of the utero-placental circulation appears to 
be under neuro-endocrine and environmental factors. 
Oestrogen increases uterine blood flow by vasodilation and 
adrenaline or noradrenaline infusions decrease utero-
placental flow by vasospasm (Greiss 1967). Angiotensin II 
infusions have a vasodilatory effect in lower doses and in 
higher doses the uterine blood flow decreases (Leib 1980). 
Maternal pyrexia (+ 1.5 deg C) has been associated with 
decreased utero-placental flow in pregnant ewes (Oakes 1976) 
and maternal exercise is associated with decreased uterine 
blood flow in several animal models (this may be due to 
catecholamine release or by pyrexia). Maternal cigarette 
smoking has been associated with decreased flow, possibly 
due to nicotine stimulation of catecholamine release. 
(Pirani 1978). 
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The question of autoregulation of the uteroplacental 
circulation has been studied in sheep (Greiss 1982) and it 
is postulated that these findings are similar in different 
mammalian species. 
Autoregulation is defined as: "local tissue mechanisms 
which act intrinsically in blood vessels to control vascular 
resistance, excluding the effect of stimulation elsewhere by 
the body." In sheep the pregnant uterus approaching term 
demonstrates a linear pressure flow relationship with a 
slope approximating to 1. In humans there appears to be a 
differential reactivity of the myo-endometrial and placental 
components of total uterine blood flow (Kauppila 1980). 
There is evidence of autoregulation in the myo-endometrial 
arteries but in the utero placental vessels there is a 
passive widely dilated system. The changes in the vascular 
system of the uterus must thus be related to the stage of 
pregnancy and are dependent upon the extent of the so-called 
normal physiological changes particularly in the spiral 
arteries. 
In early pregnancy the overall picture is similar to that of 
the non-pregnant state with only a small amount of blood 
directed to the placenta. The myometrial arteries have an 
amount of musculo-elastic tissue remaining and retain the 
ability to autoregulate. The adaptive process of 
trophoblastic invasion has not occurred to a sufficient 
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extent to alter the pattern of autoregulation seen in the 
uterus. 
In late pregnancy there is 80-90% of the total uterine blood 
flow going towards the placenta with its widely dilated 
utero-placental arteries and therefore the overall picture 
is one of passive dilation (Greiss 1982). 
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The neurendocrine and humoral regulation referred to 
previously must be effected at the vascular tree proximal to 
the utero-placental arteries. 
There is a large degree of reserve of placental function 
which can compensate for reduced placental blood flow 
without any impairment of fetal wellbeing. Separation of 
the placenta of up to 25% carries no untoward fetal effects 
(Fox 1978). In studies on hypoxic sheep and dogs it appears 
that there is an excess of oxygen diffusing capacity which 
normally exceeds fetal requirements (Power 1967, Lorijn 
1980). It is postulated that this degree of excess capacity 
of placental function makes it unnecessary for the placenta 
to possess the ability to autoregulate its blood flow. 
In labour uterine contractions result in decreased uterine 
venous outflow and arterial blood supply to the placenta. 
This is a function of the resting tone and the contraction 
amplitude and frequency (Harbert 1982). The blood flow in 
the final hour of labour has been recorded as only 66% of 
the mean of the preceeding 48hr period. It appears that the 
placental reserve is sufficient to meet the requirements of 
the fetus in the short periods of decreased flow during 
contractions. During a contraction the venous outflow of 
the intervillous space is decreased and therefore the pool 
of blood in the intervillous space is not reduced thus there 
is a continued oxygen supply, although at a reduced level 
(Ramsay 1977). 
It is obvious that if the frequency or amplitude of 
contractions exceeds a certain level in a placenta which has 
a decreased reserve then fetal distress will result. 
Maternal posture has an effect on utero-placental flow, when 
compared to the supine position the left lateral position 
has been shown to increase utero-placental blood flow 
(Kauppila 1980). 
2. Fetal 
The umbilical blood flow derives from both ventricles in 
parallel which is directed at a largely passive umbilical 
bed. There is a high umbilical artery flow to the placental 
villi which is not responsive to changes in oxygen tension 
in the maternal side of the placenta. The umbilical artery 
flow is+/- 270mls/min at term which accounts for 57% of the 
fetal cardiac output and is acutely sensitive to oxygen 
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tension in the umbilical venous and arterial blood (Dawes 
1969). 
The fetal placental blood flow has been shown to be 
decreased in pregnancies complicated by intrauterine growth 
retardation (Laurin et al 1987). Dihydralazine, which 
crosses the placenta has been shown to increase the 
umbilical artery blood flow in hypertensive pregnancy 
(Jouppila et al 1985). 
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CHAPTER 3 
THE EFFECT OF HYPERTENSION IN PREGNANCY ON UTEROPLACENTAL 
BLOOD FLOW 
When the effect of hypertension on uteroplacental blood flow 
is studied it is important to distinguish between chronic 
hypertensive states and pre-eclampsia. 
If pre-eclamptic pregnancies are studied, it is notable that 
placental blood flow is reduced (Dixon et al 1963 and Lunell 
et al 1984) although intra-uterine growth retardation is not 
a constant feature of pre-eclampsia (McGillivray et al 
1981). McGillivray noted that IUGR is an associated feature 
in 21% of cases if proteinuric hypertension is present but 
when there is only hypertension present in the second half 
of pregnancy the birth weight distribution of the 
pregnancies is normal. Lunell's findings indicate a reduced 
placental blood flow in hypertensive patients, even when 
normotensive and hypertensive women who delivered normal 
weight infants were studied and women who delivered growth 
retarded infants were excluded. The mean reduction in 
placental blood flow was estimated at 50% from his radio-
isotope studies using Indium 113 m accumulation curves. In 
addition to the presence of hypertension, the time of onset 
of the hypertension appears to be of note. In early onset 
pre-eclampsia the rate of IUGR is higher than the normal 
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(18.2%) but in late onset has been found to be less (5.6%) 
than the normal hospital incidence which was 8.6% (Long et 
al 1980) in that particular study. 
If essential hypertension is studied a different disease 
pattern is encountered. Essential hypertension in early 
pregnancy may be associated with IUGR but many women with 
this disease deliver babies of a normal size (Arias 1975). 
In view of the defective placentation (discussed in the next 
section) which occurs in pre-eclamptic pregnancies before 20 
weeks, it is difficult to understand why the occurrence of 
growth retardation is not present in all cases of pre-
eclampsia. Similarly, it is still unclear why pre-eclampsia 
may only become clinically evident in the third trimester 
when the pathology of the placental vessels is present long 
before. It may be possible that the hypertension of pre-
eclampsia is an adaptation to enable greater blood flow to 
the placenta. 
It has been found that the presence of IUGR appears to 
correlate well with the degree of plasma volume expansion 
rather than the degree of hypertension (Arias 1975). Plasma 
volume expansion is a feature of normal pregnancy (Hytten FE 
1963) and a failure of this expansion is associated with 
IUGR in chronic hypertensive women. If there is appropriate 
volume expansion, then these women will deliver babies which 
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are appropriately grown. Gallery (1979) and Soffronoff 
(1977) found an inverse correlation between the degree of 
hypertension and the plasma volume expansion but in contrast 
to Arias did not find an overall reduction in plasma volume 
in known chronic hypertensive women. 
It is clear that in both pre-eclamptic and chronic 
hypertensive pregnancy there is a reduction in plasma volume 
and in pre-eclamptic pregnancy a reduction in utero-
placental blood flow. It is postulated that utero-placental 
blood flow is reduced in chronic hypertensives on account of 
the higher incidence of IUGR. 
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CHAPTER 4 
DEFECTIVE PLACENTATION IN PRE-ECLAMPTIC PREGNANCY 
The changes in anatomy of the spiral arteries in the first 
16 weeks of pregnancy have been described in Section 1. 
When pregnancies with pre-clampsia are studied it appears 
that the second wave of trophoblastic invasion of the spiral 
arteries (which occurs from 12 - 16 weeks) is absent. 
The progressive loss of musculo-elastic tissue in the media 
of the spiral arteries of the utero-placental bed do not 
extend beyond the deciduo-myometrial junction and do not 
penetrate to the radial arteries as they do in a normal 
pregnancy (Robertson WB et al 1975). (Figure 2) 
The haemodynaemic consequences of this constricted segment 
is that placental blood flow is reduced. In addition, the 
segment of the utero-placental artery is responsive to 
vasomotor influences and therefore, conceivably, may be 
dilated by antihypertensive agents which could act at this 
site. 
The histology of these segments (Robertson et al 1975) 
indicate a specific pathological entity. With the study of 
placental bed biopsies and also caesarean hysterectomy 
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specimens it has been found that the proximal segments of 
these arteries (in common with the basal arteries and spiral 
arteries of the decidua parietalis) is involved with the 
lesion termed "acute atherosis". (Figure 3). 
By definition, acute atherosis involves lipid changes in 
smooth muscle cells, necrosis of smooth muscle, fibrinous 
vasculosis and infiltration 
macrophages. 
of the damaged wall by 
It follows that acute atherosis can only be present in the 
walls of arteries with smooth muscle present and therefore 
cannot be a feature of normal utero-placental arteries which 
have undergone replacement of their muscular wall with 
fibrinoid material. 
Robertson likens the pathological features of acute 
atherosis to the early stages of atheroma, namely, the 
accumulation of lipid in smooth muscle cells or myointimal 
cells which eventually perish freeing their lipid to be 
taken up by macrophages. The question why atherosis is the 
pathological feature of the arteries in hypertensive 
pregnancy and not the arterionecrosis of systemic 
accelerated essential hypertension has not been assessed to 
date. 
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It is notable that similar changes have been -described in 
pregnancies complicated by intrauterine growth retardation 
without hypertension (Khong et al 1986). 
The reason for the failure of the second wave of 
trophoblastic invasion and the development of a pathological 
spiral (placental) artery in pre-eclamptic pregnancy is not 
clear. It would be of immense use to the clinician involved 
with the treatment of pre-eclampsia if a compound which 
could preferentially dilate the constricted segments of the 
uteroplacental arteries and improve blood flow to the 
placenta was available. 
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CHAPTER 5 
THE INVESTIGATION OF UTERO-PLACENTAL BLOOD FLOW WITH RADIO-
ISOTOPE ACCUMULATION/DISAPPEARNCE STUDIES 
There have been a number of methods of investigation used in 
respect of the utero-placental blood flow. The 
investigation of this area is difficult as there are a 
number of different arteries supplying the uterus, the 
placenta is not at a constant site and its size varies 
according to gestational age and between patients. The 
presence of a fetus has also proved a hinderance and a 
number of methods of investigation are applicable to animal 
experimentation only. 
In human subjects the study of utero-placental blood flow 
has frequently been undertaken with radioisotope studies. 
Initially disappearance studies of locally injected isotopes 
were used. Radioactive 24Na was used by Brown et al 1953 
and Dixon et al 1963 who injected the isotope through the 
abdominal wall into the choriodecidual space and analysed 
its disappearance curve. The method provided the initial 
data to suggest that utero-placental blood flow is reduced 
in hypertensive pregnancy. This method was criticised as 
the size of the blood pool into which the sodium was 
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injected was unknown, the isotope binds to the tissue and 
the sodium recirculates thus distorting the disappearance 
curve. The second two disadvantages have been overcome with 
the use of 133xe, it does not bind to the tissues and is 
excreted via the lungs. This method was used by Lippert et 
al 1973 and permits examination of utero-placental blood 
flow at very low dosages. 
A simpler method with greater accuracy has been developed 
using the rate of accumulation (and not disappearance) into 
the placenta. If the isotope is injected intravenously and 
its rate of accumulation into the placenta is analysed a 
reproducable determination of utero-placental flow is 
obtained. Accumulation studies have been more frequently 
performed recently and the isotopes used have been 133xe, 
Indium 113m, Technetium 99m. 
Rekonen et al 1976 described an intravenous technique using 
133xe. The isotope was injected intravenously and the 
patient held her breath for 20 seconds immediately 
afterwards. Accumulation curves in the placenta were 
studied and an estimation of intervillous and myometrial 
flow obtained. This technique has provided information on 
dihydralazine (Jouppila et al 1985) which does not decrease 
intervillous flow when given by an intravenous infusion. 
Kauppila et al 1980, demonstrated a decreased intervillous 
flow in the supine compared to the left lateral position by 
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this method. In addition, Kauppila could not demonstrate 
any change in myometrial blood flow and postulated that the 
myometrial blood flow but not the intervillous flow is under 
autoregulation influences. 
The techniques of using Indium 113m and Technetium 99m are 
most widely used now as they permit examination of utero-
placental blood flow at acceptable doses of radiation (Van 
der Merwe EJ et al 1970). 
The isotopes are bound to albumin or red cells in the case 
of Technetium or to transferrin with Indium, thus there is 
minimal transfer across the placenta to the fetal 
circulation. Most authors have used the blood flow index 
(described in Chapter 7.10) to analyse the blood flow to the 
placenta. This variable allows analysis between different 
patients and within the same patient. 
In addition there are a number of different methods of 
analysis of the time-activity curves and it has been 
possible to assess the myometrial and placental components 
of the time-activity curves (Lunell N O et al 1979). 
Following this differential analysis of the two components 
of utero-placental blood flow an index of the intervillous 
perfusion has been calculated (Bodis et al 1985) in addition 
to the blood flow index. Bodis found that the intervillous 
perfusion index was prolonged in growth retarded pregnancy 
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before the blood flow index was reduced. 
Using intravenous accumulation studies hydralazine (Lunell 
et al 1983) has been found not to decrease utero-placental 
blood flow or vascular resistance. Pindolol (Lunell et al 
1984) when used in therapeutic doses does not alter utero-
placental blood flow. Labetolol (Lunell et al 1984(b)) has 
been shown by this method not to decrease utero-placental 
blood flow in hypertensive pregnancies. 
The original work of Brown et al 1953 which demonstrated the 
reduced blood flow in pre-eclampsia has been confirmed by 
the newer methods. (Lunell et al 1984(b), Philipp et al 
1986). 
As indicated above there has not been an antihypertensive 




THE ROLE OF NIFEDIPINE IN THE TREATMENT OF HYPERTENSION IN 
PREGNANCY 
Nifedipine is an antagonist of the calcium influx through 
the slow channel of the cell membrane. Nifedipine is an 
effective anti-hypertensive agent with minimal side-effects 
and well tolerated. Its place in hypertensive therapy in 
non-pregnant patients is not clearly defined (Frishman WH 
1984) but it is finding an increasing place in the treatment 
of hypertension in Groote Schuur Hospital. It is useful in 
both long-term and emergency treatment. 
Given sublingually it has an onset of action in 5 - 10 
minutes (Erbel et al 1983) and has few side effects. The 
effect of the nifedipine in lowering the BP appears to be 
proportional to the magnitude of the pretreatment BP 
(Frishman WH 1984). The drug is safe and an excessive 
hypotensive action is not a feature of its clinical use 
(Haft JI 1984). 
Additional advantages of the action of nifedipine are that 
cardiac output is maintained or increased and there may be a 
preferential vasodilatation of cerebral vessels (Payen et al 
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1984). This property may be beneficial in eclamptic 
pregnancy when cerebral ischaemia has been postulated as a 
cause of brain damage (Richards et al 1986) and an increase 
in cerebral perfusion may be protective. 
Nifedipine has also been found to cause a decrease in 
platelet aggregation (Dale et al 1983) which may be mediated 
by calcium transport across the platelet membrane. It has 
also been postulated that platelet adhesion is a factor in 
the reduced blood flow to the placenta and the 
vasoconstriction which is seen in pre-eclamptic pregnancy 
(Wallenburg et al 1986). 
Nifedipine has been reported to be successful in treating 
the hypertension of pre-eclampsia (Walters BNJ 1984) and its 
further investigation is indicated. 
Studies in pregnant goats indicate that nifedipine has no 
detrimental effect on utero-placental blood flow (Veille et 
al 1986) and in vitro studies on umbilical artery 
preparations raise the possibility of a beneficial effect of 
nifedipine in lowering the fetal placental vascular 
resistance (Margard et al 1984). 
The introduction of an antihypertensive drug which can be 
given orally (sublingually) with rapid control of blood 
pressure but without severe hypotension is a major advance 
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in treatment of hypertension in pregnancy. Cases of severe 
hypertension can be managed without invasive monitoring and 
the same drug can be used for maintenance therapy. In view 
of its efficacy and safety the further investigation of 
nifedipine in the treatment of hypertension in pregnancy and 




THE INVESTIGATION OF THE EFFECT OF NIFEDIPINE ON UTERO-
PLACENTAL BLOOD FLOW 
In view of the finding of decreased blood flow to the 
placenta as a major patho-physiological feature of pre-
eclampsia and the efficacy of nifedipine in controlling the 
hypertension of pre-eclampsia, a study of the effect of 
nifedipine on utero-placental blood flow in hypertensive 
pregnancy was undertaken. It would be necessary to 
establish that a new antihypertensive agent should be able 
to maintain, if not increase utero-placental blood flow 
before it gained acceptance in the treatment of antenatal 
cases. 
The aims of the study were three fold: 
1. To validate the indium 113m radio-isotope accumulation 
method and to assess its value as a measure of utero-
placental blood flow. 
2. To measure the utero-placental flow before and after 
nifedipine administration. 
3. To investigate the antihypertensive effect of 
nifedipine under controlled conditions in pregnant 
hypertensive patients. 
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The outline of the study was as follows: 
1. Selection of Patients 
(A) Pregnancy duration greater than 28 weeks. 
(B) Anterior placentae or placentae with a large anterior 
component which was located by ultrasound. 
(C) Singleton pregnancy. 
(D) No evidence of fetal compromise as indicated on 
cardiotocographic monitoring. 
(E) Mean maternal diastolic blood pressure equal to or 
greater than lOOmgHg in the day before the study. 
Patients were excluded if 
(A) They had received any anti-hypertensive medication in 
the previous 48 hours before the study. 
(B) The patients had received magnesium sulphate therapy. 
(C) The patient was in labour or experienced any uterine 
contractions. 
2. Consent -
Written consent was obtained from each patient. 
3. Ethical Safeguards 
The study was approved by the University of Cape Town Ethics 
and Research Committee and by the Radiation Protection 
Officer of Groote Schuur Hospital, Cape Town. 
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The total dose of Indium was 3mCu (111 mBq) per patient (1 
mCu per study) . 
The total body radiation dose for the mother was 51 mR. The 
dose to the fetal blood is 24 mR (Van der Merwe 1970) which 
is well within the limit of radiation to a pregnant woman of 
500mR (International Committee of Radiological Protection, 
Publication 26) . 
4. Preparation of Radio-isotopes 
Indium 113m was prepared from its parent isotope by eluting 
the isotope with HCL in accordance with the manufacturers 
instructions. 
The radioactivity of the eluate was checked so that the 
sample for injection contained lmCu (37mBq). 
5. Calibration of the gamma camera 
An Elscint 410 gamma camera with a medium energy parallel 
hole collimator was used. The area under study was outlined 
using a cobalt marker. The collimator was then positioned 
as closely as possible to the area of the placenta, with the 
patient positioned as described below. 
6. Positioning of patient 
The patient was positioned supine on the examining table 
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with a 30° lateral tilt with the placenta positioned 
uppermost. On the lowermost arm a Space Labs automatic blood 
pressure recorder was placed and a recording of systolic 
blood pressure, diastolic and mean arterial pressure and 
pulse rate was measured every 5 minutes. In the uppermost 
arm an intravenous cannula was inserted and attached to a 
50cc vacolitre of 4.2% NaCl and run slowly. The patient was 
supported by pillows and rested at ease throughout the 
measurements. The patient was asked not to move during the 
study. The collimator was placed as closely as possible to 
the anterior abdominal wall. 
7. Technique of recording the accumulation curves 
The Indium lmCi was injected directly into the intravenous 
cannula over a period of 3 - 5 seconds. The inflow tubing 
was sealed by way of a valve before the Indium injection. 
After the injection the valve was opened and saline allowed 
to run into the antecubital fossa. The gamma camera 
recorded the accumulation of radioactivity under the 
collimator continuously for 480 seconds. This accumulation 
curve was stored on magnetic tape. All subsequent 
recordings were made in a similar fashion apart from a 
correction for background radiation made at the beginning. 
Three recordings were made on each patient. Two baseline 
recordings at times O and 30 min. and one after the 
administration of the drug at time 60 min. 
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8. Administration of the Nifedipine 
Nifedipine 5mg (Adalat, Bayer Pharmaceuticals) was given 
after the second baseline recording at time 30 min. The 
Nifedipine was administered sublingually and the patient 
instructed to bite the capsule and chew the remainder. She 
was then given a mouthful of water and instructed to swallow 
the empty capsule. The same procedure was followed with the 
administration of the placebo capsule. 
mixture of vitamins in a gelatin capsule. 
The placebo was a 
9. Randomised selection of patients into Nifedipine or 
placebo groups 
Initially the patients were given a number at booking into 
the antenatal clinical. The last digit of this number was 
used to randomise the patients into Nifedipine or placebo 
groups. A patient with an odd last digit was given a 
placebo and a patient with an even last digit was given 
Nifedipine. 
10. Analysis of Data 
The time activity curves were stored on magnetic tapes and 
each curve was analysed at a later time. 
analysed separately but 
identical. 
the method 
Each curve was 
of analysis was 
Initially the final radio-isotope picture was studied and 
the area of the placenta outlined with a graphic pen. 
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Secondly, summed images at 10 second intervals were analysed 
and the number of counts in the placental area plotted 
against the time in a manner similar to the specimen in 
diagram Figure 4. 
After the time activity 
parameters were calculated: 
curve has been plotted two 
1. The maximum count rate (MCR) which is determined from 
the highest plateau level of the curve. 
2. The rise time RT which is the t i me taken to rise from 
TS (the time at 5% of the maximum count rate) to T95 (the 
time at 95% of the maximum count rate). 
3. The blood flow index (BFI) is determined from the 
formula: 
Blood Flow Index = Maximum Count Rate 
Rise Time 
MCR 
BFI = RT 
Thus three values of the blood flow index (BFI) are 
calculated for each patient, two before and one after the 
administration of the drug . 
The blood flow index is a measure of utero-placental blood 
flow. The maximum count rate gives an indication of the 
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size of the blood pool in the placenta and the rise time 
indicates the time taken to achieve a steady state of influx 
and eflux of blood into the placental pool. A fast rise 
time indicates either; a small placenta, a rapid blood 
influx into the placenta or a combination of the two conditions. 
By using a ration of the maximum count rate and rise time 
a correction is made for the size of the placental pool. 
Thus the utero-placental blood flow index is a measure of the 
rate of influx of blood into the placenta. 
CHAPTER 8 
RESULTS 
1. MATERNAL CHARACTERISTICS 
The two groups of patients are described in Table 1. There 
were 9 patients in each group. There were no significant 
difference between the two groups. 
2. BLOOD PRESSURE 
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The effect of Nifedipine and placebo on blood pressure in 
each patient is shown in Table 2. The mean change in blood 
pressure i.e. the difference between the BP measurements 
after the administration of Nifedipine or placebo are shown 
in a bar diagram with the standard deviations (Figure 5). 
The Nifedipine group showed a marked decrease in the 
systolic, diastolic and mean arterial pressure and an 
increased pulse rate when compared to the placebo group. 
3. BLOOD FLOW INDEX 
The individual estimations of maximum count rate (MCR), rise 
time (RT) and blood flow index (BFI) is shown in Table 3. 
When plotted on a bar diagram with the standard deviations 
(Figure 6) the outward 
estimations is notable. 
similarity between the three 
When the BFI from the first two estimations are plotted as 
in Figure 7 the correlation co-efficient can be calculated 
and reproducibility of our technique analysed. 
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STATISTICAL ANALYSIS 
1. Blood Pressure 
When the Nifedipine and placebo groups were analysed, the 
differences between the pre- and post-treatment pulse and 
blood pressure recordings were significant. A reduction in 
systolic (p < 0.02) diastolic (p < 0.01) mean arterial 
pressure (p < 0.02) and a rise in the pulse rate (p < 0.005) 
was seen in the Nifedipine group. 
The student's T-test was used for the analysis. 
2. Blood Flow Index 
{A) A correlation co-efficient between the utero-placental 
blood flow index of the first and second scans is 0.90 
(Figure 7). 
(B) There is no significant difference between the blood 
flow indices; mean count rate, rise time and utero-
placental blood flow index when the before and after 
parameters were analysed in the placebo and Nifedipine 
groups. 
The analysis of variance was used. 
SIDE-EFFECTS 
One patient in the Nifedipine group complained of a 
headache, otherwise there were no specific side-effects. 
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Patient Number 5 in the Nifedipine group experienced 
progressive discomfort from a full bladder. She could not 
be moved because of the constant position needed by the 
study. The discomfort may explain the rise in blood 
pressure after Nifedipine administration. 
The rise in the mean blood pressure seen in the control 
group may be due to anxiety and mild fatigue. The cause of 
the anxiety and fatigue is possibly that the patient were 





The study of Nifedipine on utero placental blood flow will 
be discussed with reference to the three stated aims of the 
study (Chapter 7 p.23). 
The first aim was to validate the Indium 113m radio-isotope 
accumulation method and to assess its value as a measure of 
utero-placental blood flow. From Fig. 7 it can be seen that 
there is a close correlation between the two studies which 
were performed before the administration of the Nifedipine 
or placebo. The correlation coefficient was 0.90. This 
indicates that the utero-placental blood flow index is a 
consistent determination of utero-placental blood flow in 
the conditions present in our study. 
The studies of Husslein (1985) who used a similar method of 
investigation also found a constant utero-placental blood 
flow in a placebo treated group of patients. Occasional 
difficulties were encountered in the calculation of the 
utero-placental blood flow index due to the irregular 
appearance of the time activity curves (eg. patients 5 and 7 
in the placebo group). The nature of the curves suggest 
that there was a uterine contraction during the study. 
These curves were analysed by taking the maximum value to be 
34. 
that obtained before the onset of the contraction. The 
reason why a ratio of the rise time and maximum count rate 
was used as the measure of utero-placental flow is as 
follows: The ratio takes into account the difference in 
size of the placentae in different patients. Thus a short 
rise time would indicate either a rapid blood flow into the 
placenta or a small placenta with average blood flow. By 
using the blood flow index the size of the placental blood 
pool is taken into account, and a value is obtained which 
can be used for inter patient or intrapatient estimations of 
blood flow. 
The second aim of the study was to investigate the effect of 
Nifedipine on utero-placental blood flow. As outlined in 
Chapter 5, the utero-placental blood flow is reduced in 
hypertensive pregnancy (Brown 1953, Dixon 1963, Lunell 
1984(b)) and any drug used to treat pregnant hypertensives 
should achieve blood pressure control in the mother without 
detrimental effects on utero-placental blood flow. The 
ideal drug for use in pregnancy would have a beneficial 
effect on utero-placental blood flow and increase it to 
normal levels . This could be achieved by a vasodilator 
agent which preferentially dilates the utero-placental 
vessels over the systemic vaculature causing a concomitant 
decrease in maternal blood pressure and increase in utero-
placental blood flow. In view of Nifedipine's effectiveness 
in lowering the maternal blood pressure (Walters 1984) the 
35 
investigation of the utero-placental flow is necessary 
before it can be recommended for use in antepartum cases. 
Our results suggest that following the administration of 
Nifedipine there is a relative uterine vasodilation and a 
relative decrease in uterine vascular resistance which is 
proportional to the fall in blood pressure. Nifedipine does 
not appear to have a preferential effect however on uterine 
vascular resistance or to preferentially increase utero-
placental blood flow. 
This is the first study of the effect of Nifedipine on 
utero-placental blood flow but previous studies referred to 
in Chapter 5 have not found any hypotensive agent which 
increases utero-placental blood flow. Hydralazine (Lunell 
1983) Pindolol (Lunell 1984), Labetolol (Lunell 1984(b)) and 
Prostacyclin (Husslein 1985) have all been investigated but 
found not to increase (or decrease) utero-placental blood 
flow. In view of these findings Nifedipine may have a place 
to play in both the emergency and maintenance treatment of 
pregnant hypertensives. 
The third aim of the study was to investigate the use of 
Nifedipine in the acute situation under controlled 
conditions. As the results indicate, Nifedipine, in a 5mg 
sublingual dose caused a rapid fall in materal systolic, 
diastolic and mean arterial pressure which is significant 
when compared to a control group. 
36 , 
It was a notable finding that a rise in blood pressure was 
seen in the control group under resting conditions. The 
fact that the patients were not able to move possibly made 
them progressively more uncomfortable over the course of the 
study and thus elevated the blood pressure. 
In the Nifedipine group one patient (number 5) experienced a 
slight rise in blood pressure after Nifedipine. This 
patient was feeling discomfort from a full bladder and could 
not be moved, thus it is felt that Nifedipine was not given 
a chance to be effective. 
The absence of side-effects in the Nifedipine patients was 
notable, only one patient complained of a mild headache. 
Nifedipine is suited to the emergency treatment of 
hypertensive episodes for a number of reasons: 
1. The blood pressure is lowered in relation to the 
magnitude of the pre-treatment blood pressure. 
2. Cardiac output is maintained. 
37 ' 
3. Cardiac stimulation precipitating angina or myocardial 
infarction is rarely seen. 
For these reasons blood pressure control can be undertaken 




Nifedipine, in a 5mg sublingual acute administration, causes 
a significant fall in the systolic, diastolic and mean 
arterial pressure in a mixed group of pregnant 
hypertensives. A concurrent, significant rise in the pulse 
rate was seen. 
The utero-placental blood flow index, which is a measure of 
utero-placental blood flow, was not significantly reduced 
following the administration of Nifedipine or a placebo. 
The utero-placental blood flow index was found to be a 
consistent measure of utero-placental blood flow in resting 
patients. 
In the absence of serious side-effects it can be concluded 
that Nifedipine is a safe therapy in the acute treatment of 
hypertensive states in pregnancy. 
39 
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TABLE 1 
~1ATERNAL MD FETAL CHARACTERISTICS OF THE NIFEDIPINE AND CONTROL 
GROUPS OF PATIENTS 
NIFEDIPHIE CONTROL 
n = 9 n = 9 
Mean Age (yr) 27.2 28.6 
Proteinuria 5 3 (Number of patients) 
Median Parity 2 0 
(0 - 5) (0 -4) 
Mean Gestational 
{yr) 
age 35.8 34 . 7 
Mean Birth Weight 2313 2894 (gm) 
Mean Birth Weight 14 . 1 26.4 Percentile ( %) 
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PATIENTS TREATED WITH PLACEBO 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 160 
Diastolic 99 
Mean arterial pressure 115 
Mean post-treatment blood pressure: Systolic 175 
Diastolic 99 
Mean arterial pressure 108 
Mean pre-treatment pulse rate 78 
Mean post-treatment pulse rate 83 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 210 
Rise time 66 
Blood fl ow index 3.2 
Pretreatment scan II Maximum count rate 270 
Rise time 86 
Blood flow index 3. 1 
Post-treatment Scan Maximum count rate 135 
Rise time 140 
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PATIENT DATA 
PATIENT NO.: 2 
AGE: (YRS) 36 
PARITY: . 4 
SMOKER: No 
GESTATIONAL AGE: (WKS) 35 
r 
PLACEBO/MEDICINE: Plac ebo 
PROTEINURIA: No 
HAEMOGLOBIN (9%) 1 0 
PLATELET COUNT: 259 
URIC ACID (m mol/L) 0.25 
UREA (m mol/L) 2.9 
CREATININE (m mol/L) 62 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 167 
Diastolic 114 
Mean arterial pres sure 130 
Mean post-treatment blood pressure: Systolic 177 
Diastolic 119 
Mean arterial pressure 132 
Mean pre-treatment pulse r~te 111 
Mean post-treatment pulse rate 110 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 180 
Rise time 34 
Blood fl ow index 5~3 
Pretreatment scan II Maximum count rate 173 
Rise time 42 
Blood fl ow index 4.2 
Post-treatment Scan Maximum count rate 170 
Rise time 114 
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PAT! ENT NO.: 3 
AGE: (YRS) 21 
PARITY: . 0 
SMOKER: No 
GESTATIONAL AGE: (WKS) 32 
PLACEBO/MEDICINE: Placebo 
PROTE I NU RIA: No 
HAEMOGLOBIN (g%) 10.6 
PLATELET COUNT: 253 
URIC ACID (m mol/L) 0.27 
UREA (m mol/L) 2.5 
CREATININE (m mol/L) 62 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 14 7 
Diastolic 97 
Mean arterial pressure 115 
Mean post-treatment blood pressure: Systolic 140 
Diastolic 93 
Mean arterial pressure 112 
Mean pre-treatment pulse rate 88 
r 
Mean post-treatment pulse rate 75 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 165 
Rise time 70 
Blood fl ow index 2.4 
Pretreatment scan II Maximum count rate 175 
Rise time 82 
Blood flow index 2. 1 
Post-treatment Scan Maximum count rate 175 
Rise time 79 
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PAT! ENT DATA 
PATIENT NO.: 4 
AGE: (YRS) 35 
PARITY: ~ 
SMOKER: Yes 




HAEMOGLOBIN (9%) 11.6 
PLATELET COUNT: 401 
URIC ACID (m mol/L) 0.34 
UREA (m mol/L) 2.5 
CREATININE (m mol/L) 70 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic - 143 
Diastolic 89 
Mean arterial pressure 105 
Mean post-treatment blood pressure: Systolic 141 
Diastolic 93 
Mean arterial pressure 104 
Mean pre-treatment pulse rate 83 
r 
Mean post-treatment pulse rate 80 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 160 
Rise time 78 
Blood flow index 2. 1 
Pretreatment scan II Maximum count rate 140 
Rise time 48 
Blood flow index 2.9 
Post-treatment Scan Maximum count rate 210 
Rise time 114 
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PAT! ENT DATA 
PATIENT NO.: 5 
AGE: (YRS) 25 
PARITY: ~ 3 
SMOKER: No 
GESTATIONAL AGE: (WKS) 34 
PLACEBO/MEDICINE: Placebo 
PROTE INURIA: 3+ (Cold test} 
HAEMOGLOBIN (g%) 12. 1 
PLATELET COUNT: 237 
URIC ACID {m mol/L) 0.44 
UREA (m mol/L) 5.0 
CREATININE (m mol/L) 79 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic =- 168 
Diastolic 110 
Mean arterial pressure 127 
Mean post-treatment blood pressure: Systolic 169 
Diastolic 113 
Mean arterial pressure 130 
Mean pre-treatment pulse rate 76 
Mean post-treatment pulse rate 80 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 175 
Rise time 70 
Blood fl ow index 2.5 
Pretreatment scan II Maximum count rate 170 
Rise time 83 
Blood fl ow index 2 
Post-treatment Scan Maximum count rate 210 
Rise time 79 
Blood flow index 2.7 
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PATIENT NO.: 6 
AGE: ( YRS) 20 
PARITY: • 0 
SMOKER: Yes 
GESTATIONAL AGE: (WKS) 34 
PLACEBO/MEDICINE: Placebo 
PROTEINURIA: 0.74 g/24 hr 
HAEMOGLOBIN (9%) 10.5 
PLATELET COUNT: 164 
URIC ACID (m mol/L) 0.4 
UREA (m mol/L) 3.6 
CREATININE (m mol/L) 79 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 154 
Diastolic 111 
Mean arterial pressure 125 
Mean post-treatment blood pressure: Systolic 150 
Diastolic 110 
Mean arterial pressure 125 
Mean pre-treatment pulse rate 80 
Mean post-treatment pulse rate 86 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 225 
Rise time 97 
Bl cod fl ow index 2.3 
Pretreatment scan II Maximum count rate 
Rise time 
Blood flow index 
Post-treatment Scan Maximum count rate 350 
Rise time 112 
Blood fl ow index 3. 1 
C
 

























































































































































































































































































































































































































































































































































PATIENT NO.: 7 
AGE: (YRS) 17 
PARITY: 0 
SMOKER: No 
GESTATIONAL AGE: (WKS) 36 
PLACEBO/MEDICINE: Placebo 
PROTEINURIA: No 
HAEMOGLOBIN {g%) 12 
PLATELET COUNT: 211 
URIC ACID (m mol/L) 0.32 
UREA (m mol/L) 2. 1 
CREATININE (m mol/L) 53 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic = 147 
Diastolic 94 
Mean arterial pressure 112 
Mean post-treatment blood pressure: Systolic 152 
Diastolic 98 
Mean arterial pressure 117 
Mean pre-treatment pulse rate 98 
Mean post-treatment pulse rate 90 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 190 
Rise time 122 
Blood fl ow index 1. 7 
Pretreatment scan II Maximum count rate 155 
Rise time 139 
Blood fl ow index 1. 1 
Post-treatment Scan Maximum count rate 205 
Rise time 73 
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PATIENT NO.: 8 
AGE: (YRS) 42 
PARITY: ~ 2 
SMOKER: No 
GESTATIONAL AGE: (WKS) 32 
PLACEBO/MEDICINE: Placebo 
PROTEINURIA: No 
HAEMOGLOBIN (g%) 11.9 
PLATELET COUNT: 234 
URIC ACID (m mol/L) 0. 19 
UREA (m mol/L) 1.8 
CREATININE (m mol/L) 62 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Sys t olic 138 
Diastolic 98 
Mean arterial pressure 109 
Mean post-treatment blood pressure: Systolic 140 
Diastolic 102 
Mean arterial pressure 114 
Mean pre-treatment pulse rate 85 
Mean post-treatment pulse rate 88 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 160 
Rise time 82 
Blood fl ow index 2 
Pretreatment scan II Maximum count rate 185 
Rise time 75 
Blood flow index 2.5 
Post-treatment Scan Maximum count rate 205 
Rise time 69 
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PAT! ENT DATA 
PATIENT NO.: 9 
AGE: (YRS) 30 
PARITY: - 2 
SMOKER: No 
GESTATIONAL AGE: (WKS) 38 
PLACEBO/MEDICINE: Pl acebo 
PROTEINURIA: No 
HAEMOGLOBIN (g%) 11. 7 
PLATELET COUNT: 194 
URIC ACID (m mol/L) 0.34 
UREA (m mol/L) 1.8 
CREATININE (m mol/L) 53 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: ·Systolic 128 
Diastolic 92 
Mean arterial pressure 103 
Mean post-treatment blood pressure: Systolic 128 
Diastolic 96 
Mean arterial pressure 104 
Mean pre-treatment pulse rate 80 
Mean post-treatment pulse rate 73 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 340 
Rise time 49 
Blood fl ow index 6.9 
Pretreatment scan II Maximum count rate 300 
Rise time 50 
Blood flow index 6 
Post-treatment Scan Maximum count rate 410 
Rise time 50 
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PATIENTS TREATED WITH NIFEDIPINE 
PATIENT DATA 
PATIENT NO.: 
AGE: (YRS) 34 
PARITY: . 3 
SMOKER: No 
GESTATIONAL AGE: (WKS) 37 
PLACEBO/MEDICINE: Nifedipine 
PROTEINURIA: No 
HAEMOGLOBIN (9%) 11. 3 
PLATELET COUNT: 335 
URIC ACID (m mol/L) 0.28 
UREA (m mol/L) 1.8 
CREATININE (m mol/L) 53 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 151 
Diastolic 96 
Mean arterial pressure 11 4 
Mean post-treatment blood pressure: Systolic 145 
Diastolic 89 
Mean arterial pressure 105 
Mean pre-treatment pulse rate 84 
Mean post-treatment pulse rate 81 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 300 
Rise time 47 
Blood fl ow index 6.4 
Pretreatment scan II Maximum count rate 320 
Rise time 47 
B 1 ood fl ow index 6.8 
Post-treatment Scan Maximum count rate 300 
Rise time 64 
Blood flow index 4.7 
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URIC ACID (m mol/L) 
0.35 
UREA (m mol/L) 
3.2 
CREATININE (m mol/L) 62 
-2-
1~ BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: 
Mean post-treatment blood pressure: 
Mean pre-treatment pulse rate 
Mean post-treatment pulse rate 
2. BLOOD FLOW INDICES: 
Pretreatment scan I 




Mean arterial pressure 
Systolic 
Diastolic 
Mean arterial pressure 
Maximum count rate 
Rise time 
Blood flow index 
Maximum count rate 
Rise time 
Blood flow index 
Maximum count rate 
Rise time 
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PAT! ENT NO.: 
3 











2+ (Cold t est) 




URIC ACID (m mol/L) 
0.4 5 
UREA (m mol/L) 
5.4 
CREATININE (m mol/L) 70 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 
155 
Diastolic 100 
Mean arterial pressure 115 
Mean post-treatment blood pressure: Systolic 
153 
Diastolic 102 
Mean arterial pressure 112 
Mean pre-treatment pulse rate 
105 
Mean post-treatment pulse rate 
119 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 
380 
Rise time 115 
Blood fl ow index 3.3 
Pretreatment scan II Maximum count rate 
340 
Rise time 68 
Blood fl ow index 5 
Post-treatment Scan Maximum count rate 4
70 
Rise time 103 
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PAT! ENT DATA 
PATIENT NO.: 
4 












HAEMOGLOBIN ( g%) 8.7 
PLATELET COUNT: 199 
URIC ACID (m mol/L) 0.26 
UREA (m mol/L) 3.9 
CREATININE (m mol/L) 62 
-2-
1. BLOOD PRESSURE INDICES: 




Mean arterial pressure 
113 




Mean arterial pres sure 108 
Mean pre-treatment pulse rate 
87 
Mean post-treatment pulse rate 
105 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 
290 
Rise time 51 
Blood fl ow index 5.7 
Pretreatment scan II Maximum count rate 
330 
Rise time 60 
Blood fl ow index 5.5 
Post-treatment Scan Maximum count rate 
340 
Rise time 86 
Blood fl ow index 4 
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URIC ACID (m mol/L) 
0.31 
UREA (m mol/L) 
3.2 
CREATININE (m mol/L) 62 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 150 
Diastolic 99 
Mean arterial pressure 116 
Mean post-treatment blood pressure: Systolic 155 
Diastolic 103 
Mean arterial pre ssure 121 
Mean pre-treatment pulse rate 78 
Mean post-treatment pulse rate 95 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 130 
Rise time 44 
Blood fl ow index 3.0 
Pretreatment scan II Maximum count rate 100 
Rise time 60 
Blood flow index 1. 7 
Post-treatment Scan Maximum count rate 185 
Rise time 75 
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PATIENT DATA 
PAT! ENT NO.: 
6 
AGE: (YRS) 27 
PARITY: . 
SMOKER: No 
GESTATIONAL AGE: (WKS) 38 
PLACEBO/MEDICINE: Nifedi pine 
PROTEINURIA: No 
HAEMOGLOBIN (g%) 12.2 
PLATELET COUNT: 209 
URIC ACID (m mol/L) 0.25 
UREA (m mol/L) 2.3 
CREATININE (m mol/L) 62 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 158 
Diastolic 109 
Mean arterial pressure 123 
Mean post-treatment blood pressure: Systolic 156 
Diastolic 109 
Mean arterial pressure 123 
Mean pre-treatment pulse rate 85 
Mean post-treatment pulse rate 93 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 270 
Rise time 120 
Blood fl ow index 2.3 
Pretreatment scan II Maximum count rate 250 
Rise time 102 
Blood fl ow index 2.5 
Post-treatment Scan Maximum count rate 360 
Rise time 99 
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AGE: (YRS) 25 
PARITY: ~ 2 
SMOKER: No 
GESTATIONAL AGE: (WKS) 34 
PLACEBO/MEDICINE: Nifed i pi ne 
PROTEINURIA: 1.6 g/ 24 hrs 
HAEMOGLOBIN (g%) 15 
PLATELET COUNT: 261 
URIC ACID (m mol/L) 0.41 
UREA (m mol/L) 2 .9 . 
CREATININE (m mol/L) 53 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: 
Mean post-treatment blood pressure: 
Mean pre-treatment pulse rate 
Mean post-treatment pulse rate 
2. BLOOD FLOW INDICES: 
Pretreatment scan I 




Mean arterial pres sure 
Systolic 
Diastolic 
Mean arterial pres sure 
Maximum count rate 
Rise time 
Blood fl ow index 
Maximum count rate 
Rise time 
Blood flow index 
Maximum count rate 
Rise time 
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PATIENT DATA 
PATIENT NO.: 8 
AGE: (YRS) 33 
PARITY: • 5 
SMOKER: No 
GESTATIONAL AbE: (WKS) 32 
PLACEBO/MEDICINE: Nifed i pi ne 
PROTEINURIA: 1 .4 g/24 hrs 
HAEMOGLOBIN {g%) 14.7 
PLATELET COUNT: 275 
URIC ACID (m mol/L) 0.48 
UREA (m mol/L) 3.9 
CREATININE (m mol/L) 70 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 149 
Diastolic 107 
Mean arterial pressure 120 
Mean post-treatment blood pressure: Systolic 133 
Diastolic 99 
Mean arterial pressure 110 
Mean pre-treatment pulse rate 63 
Mean post-treatment pulse rate 85 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 140 
Rise time 150 
Blood flow index 0.9 
Pretreatment scan II Maximum count rate 185 
Rise time 144 
Blood fl ow index 1.3 
Post-treatment Scan Maximum count rate !80 
Rise time 92 






































































































































































































































































































































































































































































































































PAT! ENT DATA 
PATIENT NO.: 9 
AGE: (YRS) 24 
PARITY: ~ 
SMOKER: No 
GESTATIONAL AGE: (WKS) 41 
PLACEBO/MEDICINE: Nife di pine 
PROTE INURIA: 0.38 g/ 24 hrs 
HAEMOGLOBIN (g%) 13 .8 
PLATELET COUNT: 332 
URIC ACID (m mol/L) 0.38 
UREA (m mol/L) 3.2 
CREATININE (m mol/L) 62 
-2-
1. BLOOD PRESSURE INDICES: 
Mean pre-treatment blood pressure: Systolic 138 
Diastolic 98 
Mean arterial pressure 110 
Mean post-treatment blood pressure: Systolic 128 
Diastolic 91 
Mean arterial pressure 101 
Mean pre-treatment pulse rate 78 
Mean post-treatment pulse rate 87 
2. BLOOD FLOW INDICES: 
Pretreatment scan I Maximum count rate 120 
Rise time 74 
Blood fl ow index 1.6 
Pretreatment scan II Maximum count rate 125 
Rise time 68 
Blood flow index 1.8 
Post-treatment Scan Maximum count rate 205 
Rise time 112 
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